FineHeart Receives Slovenia JAZMP (Agency for Medicinal Products and Medical Devices of the Republic of Slovenia) Authorization to Launch Its FIH Clinical Study on Patients Suffering From Advanced Heart Failure

BORDEAUX, France & LJUBLJANA, Slovenia–(BUSINESS WIRE)–FineHeart S.A., a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announces that it has received authorization from JAZMP, the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia, to begin its First-In-Human (FIH) clinical study. This prospective, non-randomized study is designed to assess the safety, implant feasibility and preliminary clinical pe

administrator

Related Articles